Why Do I Need Chemotherapy After Surgery If the Cancer Has Been Removed?

What does “all the cancer has been removed” mean?

After surgery, “the tumour was removed”, “clear margins” and “a clear scan” describe different things.

Clear margins concern the boundary of the tissue removed. They are not a whole-body test. Equally, a recommendation for further treatment is not proof that cancer remains. Your team is weighing a future risk, often when there is no detectable disease now. The surgical margins, lymph nodes and tumour features help with treatment planning.

If a margin is involved rather than clear, ask what that means for your particular operation. Decisions about further surgery, radiotherapy and medicines address different questions; chemotherapy is not an automatic solution to every margin problem.

What is chemotherapy after surgery trying to achieve?

Adjuvant chemotherapy is chemotherapy given after surgery to reduce the risk of cancer returning. Medicines can reach beyond the area where the operation took place. They may treat microscopic cancer cells that surgery and scans cannot identify.

This differs from treatment for known remaining cancer or disease that has spread to distant organs. Ask your oncologist to state the purpose clearly: “Is this treatment intended to reduce the risk of recurrence after surgery, or are we treating cancer that has been found?”

Additional treatment does not always mean chemotherapy. Depending on the diagnosis, a plan may include radiotherapy, hormone treatment, targeted medicines or immunotherapy. These treatments have different roles. Your written plan should name each treatment and explain why it is being offered.

How do doctors decide whether I need it?

The starting point is the final diagnosis. The cancer's site and type, its stage, lymph-node findings, grade and relevant biological features help estimate risk. Stage describes how far the cancer has grown or spread; findings from surgery help establish its pathological stage. Grade describes how abnormal the cells look and can give information about their behaviour. The importance of each feature varies between cancers.

Your team also needs to know what treatment you have already received. Chemotherapy given before surgery changes the discussion about what comes afterwards. Two people with the same cancer name may therefore receive different recommendations without either plan being wrong.

The discussion must include you as a person: your recovery, usual daily activities, other illnesses, organ function, previous treatment problems and priorities. A recommendation should account for both expected cancer benefit and your ability to manage treatment.

Discuss practical concerns too. Work, caring responsibilities, travel and cost can affect your plan and support needs.

How much benefit could chemotherapy give me?

Ask for two estimates: your chance of the relevant outcome without chemotherapy and with it. Both estimates should cover the same number of years and assume the same other planned treatments. A percentage about recurrence should not be compared with a percentage about survival.

An illustrative example: recurrence within five years

These numbers are hypothetical. They are not a prediction for any particular cancer or person.

The absolute reduction is 5 percentage points: 20% minus 15%. The same example could be described as a 25% relative reduction, because five is one quarter of 20. Asking for the absolute difference makes it easier to understand the size of the benefit.

These estimates describe groups of people. They cannot tell us exactly who will benefit or predict what will happen to you. Ask how reliable the estimate is, whether it is based on people with a cancer similar to yours, and how your own health and treatment affect it.

How should I weigh that benefit against side effects?

The question is what the proposed medicines could mean for you. Ask which side effects are common, which can be serious and which might continue after treatment finishes. Fatigue, nausea, mouth problems and hair loss vary with the regimen; not everyone experiences the same effects.

You can ask: “What is the likely effect on my everyday life, and what support will I have?” Discuss treatment visits, recovery between cycles, monitoring and whom to contact with problems. If a particular risk worries you, ask about it directly rather than assuming every chemotherapy medicine carries the same risk.

Consider asking someone you trust to take notes. Ask when a decision is needed.

When might chemotherapy reasonably be omitted?

For some diagnoses and risk groups, surgery and other appropriate treatment may be enough. For others, chemotherapy adds so little expected benefit that its burdens may outweigh that gain. Serious health problems or recovery difficulties may also change which options are reasonable.

For other diagnoses and risk groups, evidence may show a worthwhile reduction in recurrence or cancer deaths. Feeling well after surgery does not remove that possible benefit.

If chemotherapy is omitted, ask what treatment and follow-up remain important. Surveillance monitors for problems; it does not provide the same risk reduction as an effective adjuvant treatment. A decision to omit chemotherapy should come with an agreed plan, rather than simply ending care.

Can another test help me decide?

Sometimes. A test is useful when it has been validated for your cancer and treatment setting, and when its result could change a decision. Ask what the team would recommend for each possible result before paying for it.

In selected early breast cancers, a tumour gene-expression test can help with chemotherapy decisions. Eligibility depends on factors including hormone receptors, HER2 (human epidermal growth factor receptor 2, a protein involved in cell growth), lymph nodes and menopausal status. Our breast cancer chemotherapy guide explains these limits.

A blood test for circulating tumour DNA (ctDNA) looks for small pieces of the cancer’s genetic material in the bloodstream. A negative result does not prove that no cancer cells remain and is not, by itself, a reason to omit chemotherapy. Your team must consider the cancer type, stage, the test used and whether its result can reliably guide this treatment decision.

For people with stage 3 colon cancer, research has not established that reducing chemotherapy after a negative ctDNA blood test preserves cancer control as well as standard treatment. A negative result should therefore not be used on its own to decide that less chemotherapy is safe. This finding applies to a particular cancer and treatment setting; your team needs to explain what the test can and cannot tell you in your situation.

When should treatment start, and what needs to happen first?

There is no single deadline that applies to every cancer and operation. Final pathology, appropriate investigations and recovery need to be brought together into a timely plan. Blood tests and other assessments depend on the medicines being considered.

If you are waiting, ask what is outstanding, who is arranging it and when the next decision will be made. Tell the team about wound problems, difficulty eating or other recovery concerns. Do not decide independently to postpone recommended treatment while organising extra tests or another opinion.

Before starting, ask for a written outline of the medicines, intended duration, review schedule and contact arrangements. Understanding the next step can make an unfamiliar treatment feel more manageable.

What should I bring and ask?

Bring copies of the following, where available:

• Final operation pathology and any biomarker reports.
• Operation notes and discharge summary.
• Scan reports and the scan images or access details.
• Details of previous cancer treatment and the proposed plan.
• Your current medicines, supplements, allergies and relevant medical history.

Use these five questions as a discussion sheet:

1. What is my estimated recurrence risk, over what time period?
2. What does the proposed treatment change in absolute terms?
3. What are its main short-term and lasting burdens for me?
4. Are alternatives, including omission, reasonable in my situation?
5. What happens next, who arranges it and when?

Use these questions with your treating team to understand the recommendation and weigh the possible benefit against side effects and the demands of treatment. You can ask for explanations in everyday language and a written summary of the agreed next steps.

Bringing the discussion together

You do not need to resolve every question on your own. Bring your available reports and the questions that matter most to your treating team. Before leaving, check that you understand the agreed next step, when it should happen and whom to contact if you need help.